1. Introduction
===============

Compounds containing the 4(3*H*)-quinazolinone ring system possess various biological activities \[[@B1-pharmaceuticals-05-01282]\]. Some 2,3-diaryl-4(3H)-quinazolinone derivatives exhibit COX-2 inhibitory and anti-inflammatory activity \[[@B2-pharmaceuticals-05-01282],[@B3-pharmaceuticals-05-01282],[@B4-pharmaceuticals-05-01282]\]. The majority of COX-2 inhibitors are diaryl heterocycles. The presence of *para*-sulfonamides or *para*-sulfonylmethanes on one of the aryl rings was found to be essential for optimum COX-2 selectivity and inhibitory potency, while a wide variety of heterocycles, in general a five membered or six membered ring, can be used as the central ring system \[[@B5-pharmaceuticals-05-01282],[@B6-pharmaceuticals-05-01282]\]. The results of a molecular docking study showed that 2,3-diaryl-4(3H)-quinazolinones possessing *p*-benzene-sulfonamide moieties at C-2 and phenyl rings at N-3 were predicted to have potent COX-2 inhibitory activity. The study used SC-558 ([Figure 1](#pharmaceuticals-05-01282-f001){ref-type="fig"}) as reference ligand \[[@B7-pharmaceuticals-05-01282]\]. As continuation of our research program, we report herein the synthesis and COX-2 inhibitory activity evaluation of 4-\[(*E*)-2-(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethenyl\]benzene-1-sulfonamide and its analogs **1a-f** (Fig.1).

![Chemical structure of SC-558 \[[@B5-pharmaceuticals-05-01282]\] and general formula of the title compounds **1a-f**.](pharmaceuticals-05-01282-g001){#pharmaceuticals-05-01282-f001}

2. Results and Discussion
=========================

The title compounds **1a-f** were synthesized stepwise by the method summarized in [Scheme 1](#pharmaceuticals-05-01282-f002){ref-type="fig"} and [Scheme 2](#pharmaceuticals-05-01282-f003){ref-type="fig"}. Anthranilic acid (**2**) was reacted with acetic anhydride (**3**) at reflux temperature for 1 hour to provide benzoxazinone **4** \[[@B8-pharmaceuticals-05-01282]\]. Treatment of **4** with corresponding anilines **5a-f** in glacial acetic acid under reflux conditions for 6-7 hours gave 2-methyl-3-phenyl-4(3*H*)-quinazolinones **6a-f** \[[@B1-pharmaceuticals-05-01282],[@B8-pharmaceuticals-05-01282],[@B9-pharmaceuticals-05-01282]\]. 4-Formylbenzenesulfonamide (**7**) was synthesized from sulfanilamide (**8**). Diazotization of **8** led to diazonium salt **9**, which was then neutralized with sodium carbonate and added dropwise into CuCN/KCN (Sandmeyer reaction) to yield benzonitrile **10**. Reduction of **10** with Raney nickel alloy in 75% aqueous formic acid gave 4-formylbenzenesulfonamide (**7**) \[[@B10-pharmaceuticals-05-01282]\]. Finally, the condensation of **6a-f** and **7** in the presence of anhydrous sodium acetate as catalyst and glacial acetic acid as solvent at 90 °C for 4 hours (TLC monitoring) afforded the title compounds **1a-f** \[[@B11-pharmaceuticals-05-01282],[@B12-pharmaceuticals-05-01282]\].

The IR spectra of compounds **1a-f** showed absorption bands at 3,331--3,365 and 3,200--3,265 cm^-1^ due to the presence of the NH~2~ group. The bands at 1,330--1,340 and 1,163--1,166 cm^-1^ correspond to ‑SO~2~-, while the carbonyl groups of the quinazolinones are observed as strong bands at 1,654--1,691 cm^-1^. In the ^1^H-NMR spectra the two protons of the sulfonamide NH~2~ group appear as a broad singlet at δ 7.40 ppm, while the presence of the two protons of the --(*E*)-ethenyl chain of the compounds are observed as doublets at 6.43--6.51 ppm (1H, *J* = 15,0 Hz) and 7.87--7.91 (1H, *J* = 15,0 Hz), respectively. The structures were further supported by ^13^C-NMR and HR-ESI-MS of the compounds which showed the complete agreement with the assigned molecular structures.

![Synthesis of the title compounds **1a-f**.](pharmaceuticals-05-01282-g002){#pharmaceuticals-05-01282-f002}

![Synthesis of 4-formylbenzenesulfonamide (**7**).](pharmaceuticals-05-01282-g003){#pharmaceuticals-05-01282-f003}

The results of the COX-2 inhibition screening assay of the compounds (at concentrations of 10, 20 and 50 μM) are listed in [Table 1](#pharmaceuticals-05-01282-t001){ref-type="table"}. Compound **1a** is inactive as a COX-2 inhibitor, while compounds **1b-f** are active. These data indicated that the substituent at the *para*-position of the 3-phenyl rings is essential for their inhibitory activity. In the present series, 4-\[(*E*)-2-{3-(4-methoxyphenyl)-4-oxo-3-4-dihydroquinazolin-2-yl}ethenyl\]benzene-1-sulfonamide (**1c**) showed a maximum COX-2 inhibition (47.1%) at a concentration of 20 μM. All our compounds are less potent COX-2 inhibitors than celecoxib (which showed 80.1% inhibition at a concentration of 1 μM), but the COX-2 inhibitory activity of the most active compound is somewhat higher than that of 2-(4-nitrophenyl)-3-(tolyl)-4(3*H*)-quinazolinone reported earlier (which showed a maximum COX-2 inhibition of 27.72% at a concentration of 22 μM) \[[@B4-pharmaceuticals-05-01282]\]. The solubility of the compounds in the assay system used is poor, and at concentrations of 50 μM the compounds do not dissolve completely.
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###### 

*In vitro* COX-2 inhibition data (%) for compounds **1a-f** (see [Figure 1](#pharmaceuticals-05-01282-f001){ref-type="fig"}).

  Compd                    *X*                                                     Inhibition ± SD (%)^1)^ at concentration of               
  ------------------------ ------------------------------------------------------- --------------------------------------------- ----------- -----------
  **1a**                   H                                                       ns                                            ns          ns
  **1b**                   CH~3~                                                   21.2 ±1.4                                     17.4 ±1.3   30.6 ±2.7
  **1c**                   OCH~3~                                                  39.1 ±0.9                                     47.1 ±4.3   38.2 ±2.3
  **1d**                   Br                                                      29.2 ±1.2                                     36.3 ±3.6   33.7 ±2.3
  **1e**                   Cl                                                      ns                                            27.2 ±1.8   38.4 ±3.8
  **1f**                   COOC~2~H~5~                                             10.8 ±0.5                                     36.7 ±1.6   33.9 ±3.0
  **Reference compound**   **Inhibition ± SD (%)^1)^ at** **1 μM concentration**                                                             
  Celecoxib                80.1 ±2.7                                                                                                         

Values are the mean (*n* = 3) and SD (Standard deviation) of the % inhibition acquired using COX inhibition assay kit (Catalog No. 560131, Cayman Chemical Co., Ann Arbor, MI, USA); ns = not significant (%-inhibition \<10%).

3. Experimental
===============

3.1. Chemistry. General Procedures
----------------------------------

All solvents, chemicals, and reagents were obtained commercially and used without purification. Purity tests of the products was performed by the TLC method on silica gel 60 F254 plates (Merck). Melting points were determined in the capillary tube using melting point apparatus (Stuart Scientific) and are uncorrected. Infrared (IR) spectra were recorded on a FTIR spectrophotometer (8400S, Shimadzu), ^1^H-NMR and ^13^C-NMR spectra were recorded on a JEOL JNM 500 spectrometer, using TMS as internal standard, and high resolution mass spectra (HRMS) were measured with a Waters LCT Premier XE (ESI-TOF) system in positive mode.

*4-\[(E)-2-(4-oxo-3-phenyl-3,4-quinazolin-2-yl)ethenyl\]benzene-1-sulfonamide* (**1a**): A mixture of 2-methyl-3-phenyl-4(3*H*)-quinazolinone (**6a**; 0.98 g, 5 mmol), 4-formylbenzenesulfonamide (**7**; 1.02 g, 5.5 mmol) and anhydrous sodium acetate (1 g) were dissolved in glacial acetic acid (6 mL) and refluxed at 100 °C. The progress of the reaction was monitored by TLC. After the reaction was completed, the reaction mixture was poured onto cold water and filtered off through a Buchner funnel. The solid product was washed with cold water, recrystallized from suitable solvents and dried in vacuum oven at 85 °C for 1 hour to provide **1a** as pale yellow crystalline powder (57.9% yield, recrystallized from acetonitril-water, and washed with cold ethanol), m.p. 277-278 °C. IR (KBr), □~max~, cm^-1^: 3,362, 3,234 (primary sulfonamide N-H streching), 3,049 (aromatic/alkene C-H streching), 1,672 (C=O lactam), 1,556 (C=C), 1,340, 1,165 (sulfonamide asymmetric and symmetric SO~2~ streching). ^1^H-NMR (DMSO-d~6~), δ/ppm: 8.16 (1H, dd, *J* = 7.1, 1.9 Hz, 5-H~quinazolinone~), 7.88 (1H, td, *J* = 7.1, 1.9 Hz, 7-H~quinazolinone~), 7.87 (1H, d, *J* = 15.5 Hz, 2-H~trans\ ethenyl~), 7.80 (1H, d, *J* = 7.8 Hz, 8-H~quinazolinone~) 7.74 (2H, d, *J* = 8.4 Hz, 2",6"-H~Ar~), 7.53-7.63 (6H, m, overlap of 6-H~quinazolinone~, 3",5"; 2',6'; and 4'-H~Ar~), 7.48 (2H, d, *J* = 8.45 Hz, 3',5'-H~Ar~), 7.39 (2H, s broad, NH~2\ sulfonamide~), and 6.43 (1H, d, *J* = 15.5 Hz, 1-H~trans\ ethenyl~). ^13^C-NMR (DMSO-d6, 125 MHz, TMS), δ/ppm: 161.2 ([C]{.ul}(=O)-N), C-4~quinazolinone~, 151.1 (N-[C]{.ul}=N-, C-2~quinazolinone~ ), 147.3 (C~Phe-N=C~, C-9~quinazolinone~), 144.5 (C-1"~Phe-1"-sulfonamide~), 138.0, 137.1, 136.8, 134.9, 130.0, 129.7, 129.3, 127.9, 127.3, 126.9, 126.5, 126.3, 122.6, and 120.8 (C aromatic and C ethenyl)**.**HRESIMS (*m/z*): found 404.1046 (\[M+H\]^+^), calculated masses of C~22~H~18~N~3~O~3~S: 404.1069 (error 5.7 ppm).

*4-\[(E)-2-{3-(4-methylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl}ethenyl\]benzene-1-sulfonamide* (**1b**)**:** Compound **1b** was prepared as a pale yellow crystalline powder from 2-methyl-3-(4-methylphenyl)-4(3*H*)-quinazolinone (**6b**) using the procedure described for **1a** (35.8% yield, recrystallized from THF-ethanol, followed by chloroform), m.p. 244-245 °C. IR (KBr), □~max~, cm^-1^: 3,329, 3,265 (primary sulfonamide N-H streching), 3,063 (aromatic/alkene C-H streching), 1,691 (C=O lactam), 1,550 (C=C), 1,340, 1,165 (sulfonamide asymmetric and symmetric SO~2~ streching). ^1^H-NMR (DMSO-d~6~) δ/ppm: 8.14 (1H, dd, *J* = 7.8; 1.3 Hz, 5-H~quinazolinone~), 7.90 (1H, td, *J* = 8.9, 1.9 Hz, 7-H~quinazolinone~), 7.89 (1H, d, *J* = 15.5 Hz, 2-H~trans\ ethenyl~), 7.80 (1H, d, *J* = 6 Hz, 8-H~quinazolinone~), 7.78 (2H, d, *J* = 8.4 Hz, 2",6"-H~Phe-1"-sulfonamide~), 7.56 (1H, td, *J* = 6.5; 1.3 Hz, 6-H~quinazolinone~), 7.53 (2H, d, *J* = 8.5 Hz, 3",5"-H~Phe-1"-sulfonamide~), 7.42 (2H, s, NH~2sulfonamide~), 7.37 (2H, d, *J* = 8.45 Hz, 2',6'-H~Ar~), 7,34 (2H, d, *J* = 7.8 Hz, 3',5'-H~Ar~), 6,43 (1H, d, *J* = 15.5 Hz, 1-H~trans\ ethenyl~), 2,44 (3H, s, C[H]{.ul}~3~-Ar). ^13^C-NMR (DMSO-d~6~) δ/ppm: 161.2 ((C(=O)-N), C-4~quinazolinone~), 151.1 (N-C=N-, C-2~quinazolinone~), 147.2 (C~Phe-N=C~, C-9~quinazolinone~), 144.5 (C-1"~Phe-1"-sulfonamide~), 138.7, 138.0, 137.1, 136.8, 134.9, 134.8, 130.1, 128.6, 127.9, 127.3, 126.8, 126.3, 122.6, 120.7 (C aromatic and C ethenyl), and 20.4 (C[H]{.ul}~3~-Ar). HRESIMS (*m/z*): found 418.1237 (\[M+H\]^+^), calculated masses of C~23~H~20~N~3~O~3~S: 418.1225 (error 2.9 ppm).

*4-\[(E)-2-{3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl}ethenyl\]benzene-1-sulfonamide* (**1c**)**:** Compound **1c** was prepared from 2-methyl-3-(4-methoxyphenyl)-4(3*H*)-quinazolinone (**6c**) using the procedure described for **1a** as a pale yellow crystalline powder (45.5% yield, recrystallized from ethanol), m.p. 228-229 °C. IR (KBr), □~max~, cm^-1^: 3,365, 3,246 (primary sulfonamide N-H streching), 3,080 (aromatic/alkene C-H streching), 1,675 (C=O lactam), 1,555 (C=C), 1,338, 1,163 (sulfonamide asymmetric and symmetric SO~2~ streching) and 1,250 (Ar-O-Al ether). ^1^H-NMR (DMSO-d~6~) δ/ppm: 8.14 (1H, dd, *J* = 7.8; 1.3 Hz, 5-H~quinazolinone~), 7.88 (1H, td, *J* = 7.0; 1.9 Hz, 7-H~quinazolinone~), 7,90 (1H, d, *J* = 15.6 Hz, 2-H~trans\ ethenyl~), 7.77-7.80 (3H, overlap, d, *J* = 8.4 Hz, H~Ar~), 7.55 (1H, t, *J* = 7.9 Hz, 6-H~quinazolinone~), 7.58 (2H, d, *J* = 8.5 Hz (3",5"-H~Phe-1"-sulfonamide~), 7,39 (2H, d, *J* = 6.5 Hz, (2',6'-H~Phe-4'-OMe~), 7.34 (2H, d, *J* = 7.2 Hz, (3',5'-H~Phe-4'-OMe~)), 7,42 (2H, s, NH~2sulfonamide~), 6,51 (1H, d, *J* = 15.6 Hz, 1-H~trans\ ethenyl~) and 3.86 (3H, s, CH~3~O-). ^13^C-NMR (DMSO-d~6~) δ/ppm: 161.4 ((C(=O)-N), C-4~quinazolinone~), 159.5 (C-4'~Phe-O~), 151.5 (N-C=N-, C-2~quinazolinone~), 147.3 (C~Phe-N=C~, C-9~quinazolinone~), 144.5 (C-1"~Phe-1"-sulfonamide~), 138.0, 136.9, 134.7, 130.0, 129.2, 127.9, 127.3, 126,8, 126.5, 126,3, 122.7, 120.7, 114.8 (C aromatic and C ethenyl), and 55.4 (methoxy). HRESIMS (*m/z*): found 434.1176 (\[M+H\]^+^), calculated masses of C~23~H~20~N~3~O~4~S: 434.1175 (error 0.2 ppm).

*4-\[(E)-2-{3-(4-bromophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl}ethenyl\]benzene-1-sulfonamide* (**1d**): Compound **1d** was prepared from 2-methyl-3-(4-bromophenyl)-4(3*H*)-quinazolinone (**6d**) using the procedure described for **1a** as a pale yellow crystalline powder (41.2% yield, recrystallized from ethanol), m.p. 211-212 °C. IR (KBr), □~max~, cm^-1^: 3,335, 3,236 (primary sulfonamide N-H streching), 3,095 (aromatic/alkene C-H streching), 1,683 (C=O lactam), 1,556 (C=C), 1,338, 1,165 (sulfonamide asymmetric and symmetric SO~2~ streching). ^1^H-NMR (DMSO-d~6~) δ/ppm: 8.14 (1H, dd, *J* = 7.8; 1.3 Hz, 5-H~quinazolinone~), 7.88 (1H, td, *J* = 7.0; 1.3 Hz, 7-H~quinazolinone~), 7.93 (1H, d, *J* = 15.0 Hz, 1H, 2-H~trans\ ethenyl~), 7.78-7.83 (5H, m, overlap, H~Ar~), 7.63 (2H, d, *J* = 8.5 Hz, 2',6'-H ~Phe-4'-Br~), 7.57 (1H, t, *J* = 7.8 Hz, 6-H~quinazolinone~), 7.48 (2H, d, *J* = 7.2 Hz, 3',5'-H ~Phe-4'-Br~), 7.4 (2H, s, NH~2\ sulfonamide~), and 6.5 (1H, d, *J* = 15.0 Hz, 1-H~trans\ ethenyl~). ^13^C-NMR (DMSO-d~6~) δ/ppm: 161.1 ((C(=O)-N), C-4~quinazolinone~), 150.9 (N-C=N-, C-2~quinazolinone~), 147.2 (C~Phe-N=C~, C-9~quinazolinone~), 144.6 (C-1"~Phe-1"-sulfonamide~), 137.9, 137.4, 136.1, 134.9, 132.7, 131.3, 128.1, 127.3, 126.9, 126.3, 120.6, 122.5, 122.4 (C aromatic and C ethenyl). HRESIMS (*m/z*): found 482.0164 (\[M+H\]^+^, 95%) and 484.0157 (\[M+H\]^+^, 100%), calculated masses of C~22~H~17~N~3~O~3~SBr: 482.0174 (error 2.1 ppm).

*4-\[(E)-2-{3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl}ethenyl\]benzene-1-sulfonamide* (**1e**): Compound **1e** was prepared from 2-methyl-3-(4-chlorophenyl)-4(3*H*)-quinazolinone (**6e**) using the the procedure described for **1a** as a pale yellow crystalline powder (49.5% yield, recrystallized from THF-ethanol, followed chloroform), m.p. 248-249 °C. IR (KBr), □~max~, cm^-1^: 3340, 3200 (primary sulfonamide N-H streching), 3066 (aromatic/alkene C-H streching), 1672 (C=O lactam), 1552 (C=C), and 1330, 1166 (sulfonamide asymmetric and symmetric SO~2~ streching). ^1^H-NMR (DMSO-d~6~) δ/ppm: 8.14 (1H, dd, *J* = 7.8; 1.3 Hz, 5-H~quinazolinone~), 7.88 (1H, td, *J* = 7.8; 1.3 Hz, 7-H~quinazolinone~), 7.91 (1H, d, *J* = 15,0 Hz, 2-H~trans\ ethenyl~), 7.8 (1H, t, *J* = 8 Hz, 6-H~quinazolinone~), 7.79 (2H, d, *J* = 8.4 Hz, 2",6"-H~Phe-1"-sulfonamide~), 7.68 (2H, d, *J* = 8.5 Hz, 3",5"H-~Phe-1"-sulfonamide~), 7.63 (2H, d, *J* = 7.8 Hz, 2',6'H~-Phe-4'-Cl~), 7.54 (2H, d, *J* = 10 Hz, 3',5'-H~Phe-4'-Cl~), 7.4 (2H, s, NH~2\ sulfonamide~), 7.57 (1H, d, *J* = 7.15 Hz, 8-H~quinazolinone~), 6.5 (1H, d, *J* = 15.0 Hz, 1-H~trans\ ethenyl~). ^13^C-NMR (DMSO-d~6~) δ/ppm: 161.2 ((C(=O)-N), C-4~quinazolinone~), 150.9 (N-C=N-, C-2~quinazolinone~), 147.2 (C~Phe-N=C~, C-9~quinazolinone~), 144.6 (C-1"~Phe-1"-sulfonamide~), 137.9, 137.4, 135.7, 134.9, 133.3, 130.9, 129.7, 128.1, 127.3, 126.9, 126.5, 126.3, 120.7 (C aromatic and C ethenyl). HRESIMS (*m/z*): found 438.0674 (\[M+H\]^+^, 100%), 440,0647 (\[M+H\]^+^, 40%), calculated masses of C~22~H~17~N~3~O~3~SCl: 438,0679 (error 1.1 ppm).

*Ethyl 4-{4-okso-2-\[(E)-2-(4-sulfamoylphenyl)ethenyl\]-3,4-dihydroquinazolin-3-yl}benzoate* (**1f**)**:**Compound **1f** was prepared from ethyl 4-(2-methyl-4-oxo-3,4-dihydroquinazolin-3-yl)benzoate (**6f**) using the procedure described for **1a** as a pale yellow crystalline powder (50,2% yield, recrystallized from THF-ethanol, and washed with cold ethanol), m.p. 239-240 °C. IR (KBr), □~max~, cm^-1^: 3,331, 3,219 (primary sulfonamide N-H streching), 3,100 (aromatic/alkene C-H streching), 2,960-1,983 (alipatic C-H streching), 1,701 (C=O ester), 1,654 (C=O lactam), 1,556 (C=C), and 1,340, 1,165 (sulfonamide asymmetric and symmetric SO~2~ streching). ^1^H-NMR (DMSO-d~6~) δ/ppm: 8.15 (1H, dd, *J* = 8.4; 1.3 Hz, 5-H~quinazolinone~), 8.17 (2H, d, *J* = 8.5 Hz, 2',6'~-Phe-1'-COOEt~), 7.93 (1H, d, *J* = 15.5 Hz, 2-H~trans\ ethenyl~), 7.91 (1H, td, *J* = 7.1; 1.9 Hz, 7-H~quinazolinone~), 7.81 (1H, d, *J* = 7.8 Hz, 8-H~quinazolinone~), 7.76 (2H, d, *J* = 8.5 Hz, 3",5"-H-~Phe-4"-sulfonamide~), 7.66 (2H, d, *J* = 6.5 Hz, 3',5'~-~H~Phe-1'-COOEt~), 7.61 (2H, d, *J* = 7.8 Hz, H-2",6"-~Phe-4"-sulfonamide~ ), 7.57 (1H, t, *J* = 8.5 Hz, 6-H~quinazolinone~), 7.39 (2H, s, NH~2\ sulfonamide~), 6.45 (1H, d, *J* = 15.5 Hz, 1-H~trans\ ethenyl~). ^13^C-NMR (DMSO-d~6~) δ/ppm: 165.1 (C=O ester), 161.1 (C(=O)-N), C-4~quinazolinone~), 150.6 (N-C=N-, C-2~quinazolinone~), 147.2 (C~Phe-N=C~, C-9~quinazolinone~), 144.6 (C-1'-~Phe-1'-COOEt~), 141.0 (C-4"~Phe-4"-sulfonamide~), 137.6, 137.5, 134.9, 130.5, 130.4, 129.6, 128.1, 127.3, 127.0, 126.5, 126.2, 120.6 (C aromatic and C ethenyl), 61.1 (CH~2~-O-) and 14.1 (CH~3~-C). HRESIMS (*m/z*): found 476.1278 (\[M+H\]^+^), calculated masses of C~25~H~22~N~3~O~5~S: 476.1280 (error 0.4 ppm).

3.2. In Vitro Cyclooxygenase-2 (COX-2) Inhibition Assays
--------------------------------------------------------

The ability of the test compounds **1a-f** listed in [Table 1](#pharmaceuticals-05-01282-t001){ref-type="table"} to inhibit the ability of COX-2 to catalyze the conversion of arachidonic acid to prostaglandin H~2~ (PGH~2~) was determined using a COX inhibitor screening assay kit (catalog No. 560131, Cayman Chemical Co., Ann Arbor, MI, USA) according to the manufacturer's instructions. Celecoxib was used as reference compound. The test compounds were dissolved in DMSO and added 20 μL to COX reaction tube to get final concentration mentioned at [Table 1](#pharmaceuticals-05-01282-t001){ref-type="table"}.

4. Conclusions
==============

A series of 3-phenyl-2-\[(*E*)-2-phenylethenyl\]-3,4-dihydroquinazolin-4-ones possessing *para*-sulfonamide groups on the phenyl rings of the 2-phenylethenyl moiety and various substituents (*X*= H, CH~3~, OCH~3~, Br, Cl, COOC~2~H~5~) at the *para-*position of the 3-phenyl rings were synthesized and their COX-2 inhibitory activity evaluated. The compounds having substituents at the *para*-position of the 3-phenyl ring showed COX-2 inhibitory activity. All our compounds are less potent COX-2 inhibitors than celecoxib. 4-\[(*E*)-2-{3-(4-Methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl}ethenyl\]benzene-1-sulfonamide showed a maximum COX-2 inhibition (47.1%) at concentration of 20 μM.
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